Neusoft Group (600718): Awarded the procurement project of Rushan City People's Hospital, with a bid amount of 13.7 million yuan

NightAirdropper · 2026-03-07T04:13:28+00:00

Neusoft Corporation wins the bid for the Rushan City People's Hospital Level 5 Electronic Medical Record Construction Project, with a contract amount of 13.7 million yuan. In 2024, the company's operating revenue is 11.56 billion yuan, with a net profit decrease of 14.70%, and its main products are primarily software services.

NightAirdropper

2026-03-07 04:13:28

Abstract generation in progress

Tongbi Finance News: According to Qichacha, based on the “Public Tender Announcement for the Construction of Level 5 Electronic Medical Records at Rushan People’s Hospital,” Neusoft Corporation announced on March 7, 2026, that it won the bid for the Rushan People’s Hospital procurement project, with a bid amount of 13.7 million yuan.

Related listed company: Neusoft Corporation (600718.SH)

Tongbi Finance Tips:

Neusoft Corporation (600718.SH) reported a revenue of 11.56 billion yuan in 2024, with a revenue growth rate of 9.64%. Net profit attributable to the parent company was 63 million yuan, with a net profit growth rate of -14.70%. Return on equity was 0.66%.

In the first half of 2025, the company’s revenue was 4.689 billion yuan, with a growth rate of 9.08%. Net profit attributable to the parent was 56 million yuan, with a growth rate of -42.75%.

The company currently belongs to the information technology industry. Its main product types include ERP software, firewall software, software outsourcing services, and industry-specific software. In 2024, the main business composition was autonomous software, products, and services (including medical equipment and Xikang): 83.94%; system integration: 14.37%; property advertising: 1.69%.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.